- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07698314
A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer (Myo-EXERTBC)
Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials Contact
- Telefonnummer: 412-330-6151
- E-post: ctgov@ahn.org
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Rekruttering
- Allegheny General Hospital
-
Ta kontakt med:
- Clinical Trials Contact
- Telefonnummer: 4123306151
- E-post: ctgov@ahn.org
-
Pittsburgh, Pennsylvania, Forente stater, 15212
- Har ikke rekruttert ennå
- AHN Allegheny General Hospital
-
Ta kontakt med:
- Clinical Trials Contact
- Telefonnummer: 412-330-6151
- E-post: clinicaltrials@ahn.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Pregnant women
- Males
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Conditioning Regimen Group
|
Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training". |
|
Eksperimentell: Strength Regimen Group
|
Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8". |
|
Eksperimentell: Hypertrophy Regimen Group
|
Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm". |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Myokine Production After First Exercise Session
Tidsramme: Immediately before and immediately after the first exercise session.
|
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined. |
Immediately before and immediately after the first exercise session.
|
|
Change in Myokine Production After Final Exercise Session of Each Week
Tidsramme: Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
|
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined. |
Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
|
|
Change in Myokine Production After Final Exercise Session of the Month (End of Study)
Tidsramme: Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
|
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined. |
Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Colin Champ, MD, AHN Radiation Oncology
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Hudsykdommer
- Bryst sykdommer
- Hud- og bindevevssykdommer
- Neoplasmer
- Brystneoplasmer
- Motorisk aktivitet
- Bevegelse
- Muskel- og skjelettfysiologiske fenomener
- Muskel- og skjelett og nevrale fysiologiske fenomener
- Terapeutikk
- Fysioterapi -modaliteter
- Pasientbehandling
- Treningsterapi
- Rehabilitering
- Ettervern
- Kontinuitet i pasientbehandling
- Fysisk kondisjonering, menneskelig
- Øvelse
- Motstandstrening
Andre studie-ID-numre
- 2026-125
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .